Home » Stocks » DTIL

Precision BioSciences, Inc. (DTIL)

Stock Price: $9.64 USD -0.29 (-2.92%)
Updated Aug 3, 2021 2:15 PM EDT - Market open
Market Cap 566.76M
Revenue (ttm) 33.64M
Net Income (ttm) -100.86M
Shares Out 56.63M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $9.64
Previous Close $9.93
Change ($) -0.29
Change (%) -2.92%
Day's Open 9.92
Day's Range 9.64 - 9.92
Day's Volume 211,878
52-Week Range 4.46 - 16.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) PBCAR19B is an immune-evadin...

1 month ago - Benzinga

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

1 month ago - Business Wire

Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in...

1 month ago - Zacks Investment Research

Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.  In the...

Other stocks mentioned: SWTX
1 month ago - Benzinga

DURHAM, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with...

Other stocks mentioned: SWTX
1 month ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome ...

1 month ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome ...

2 months ago - Business Wire

Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19. Data will be presented at the...

2 months ago - Benzinga

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that ...

2 months ago - Business Wire

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($0.33), which beat the estimate...

2 months ago - Benzinga

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

2 months ago - Business Wire

Precision BioSciences Inc (NASDAQ: DTIL) has announced new in vivo data using ARCUS genome editing platform resulting from a preclinical research collaboration with investigators at the University of Pe...

2 months ago - Benzinga

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that ...

3 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that ...

3 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...

3 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome ...

3 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.

3 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Derek Jantz, CSO and Co-Founder of Precision BioSciences, will participate in a fireside chat at Truist Securities Life Sciences Virtual Series.

3 months ago - Business Wire

Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer

3 months ago - GlobeNewsWire

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with...

4 months ago - GlobeNewsWire

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Precision BioSciences (NASDAQ:DTIL) moved higher by 2.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 22.22% year over year to ($...

4 months ago - Benzinga

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 f...

4 months ago - GlobeNewsWire

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs) after ...

5 months ago - Benzinga

Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy

5 months ago - GlobeNewsWire

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

6 months ago - Zacks Investment Research

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, a...

Other stocks mentioned: COCP
6 months ago - Benzinga

Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin ...

6 months ago - GlobeNewsWire

DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...

6 months ago - GlobeNewsWire

DTIL has three business lines, all of which include important collaborations with large companies. Recent results in CAR-T therapies have been very encouraging.

7 months ago - Seeking Alpha

DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome...

7 months ago - GlobeNewsWire

Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)

7 months ago - GlobeNewsWire

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...

8 months ago - GlobeNewsWire

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive lice...

Other stocks mentioned: LLY
8 months ago - PRNewsWire

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which beat the e...

8 months ago - Benzinga

Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors

8 months ago - GlobeNewsWire

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...

9 months ago - GlobeNewsWire

Precision BioSciences, Inc. is a life sciences company focused on utilizing its ARCUS genome editing platform to primarily treat human diseases and secondarily to provide food/agricultural solutions. Pr...

9 months ago - Seeking Alpha

PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings

9 months ago - GlobeNewsWire

DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with ...

9 months ago - GlobeNewsWire

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies wi...

10 months ago - GlobeNewsWire

Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR...

10 months ago - GlobeNewsWire

About DTIL

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with re... [Read more...]

Industry
Biotechnology
IPO Date
Mar 28, 2019
CEO
Matthew Kane
Employees
237
Stock Exchange
NASDAQ
Ticker Symbol
DTIL
Full Company Profile

Financial Performance

In 2020, DTIL's revenue was $24.29 million, an increase of 9.20% compared to the previous year's $22.24 million. Losses were -$109.01 million, 17.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is 18.88, which is an increase of 95.85% from the latest price.

Price Target
$18.88
(95.85% upside)
Analyst Consensus: Buy